期刊文献+

长托宁治疗COPD急性加重期临床疗效评价 被引量:1

下载PDF
导出
摘要 目的评价盐酸戊乙奎醚(长托宁)在COPD急性发作期的临床疗效。方法治疗组:基础治疗十雾化吸入盐酸戊乙奎醚(长托宁)lmg+生理盐水15ml以雾化吸人,2次/d,疗程14d;对照组:给予常规基础治疗,包括吸氧、抗炎、解痉、化痰等。结果治疗组临床总有效率为90%,有效病例中咳喘症状缓解起效时间为1~7d,平均(3.8±2.3)d。对照组临床总有效率为80%,有效病例中咳喘症状缓解起效时间为4~9d,平均(6.8±1.7)d。两组患者治疗前后肺功能改善情况对比有显著改善。结论应用抗胆碱药物可以降低胆碱能神经张力,扩张支气管,达到良好的平喘效果,所以新型抗胆碱能药物成为治疗AECOPD的有效药物之一。
作者 赵清齐 张会
出处 《中国实用医药》 2009年第19期164-166,共3页 China Practical Medicine
  • 相关文献

参考文献10

  • 1姚婉贞,王国扬.慢性阻塞性肺疾病的气道毒蕈碱M受体变化与抗胆碱治疗的研究[J].中华结核和呼吸杂志,2005,28(7):484-485. 被引量:31
  • 2Donald PT, Christopher BC. The role of lung-acting bronchodilators in the management of stable COPD. Chest,2004,125 ( 1 ) :249-259.
  • 3Donohue JF. Therapeutic response in athma and COPD. Cheat, 2004.126(2) :125-126.
  • 4慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2002,25(8):453-460. 被引量:5103
  • 5于文成 刘忠强.慢性阻塞性肺疾病患者血清中乙酰胆碱受体抗体水平的探讨[J].中华结核和呼吸杂志,1999,22(2):73-73.
  • 6Barnes PJ. Muscarinic subtypes in airway. Life Sci, 1993,52: 521-527.
  • 7Eglen RM, Reddy H, Watson N, et al. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol Sci, 1994,15 : 114-119.
  • 8沈宁,姚婉贞,朱红,赵鸣武.慢性阻塞性肺疾病患者肺组织胆碱能M受体及其亚型的变化[J].中华结核和呼吸杂志,2001,24(4):212-214. 被引量:26
  • 9Cazzola M, Matera MG. Bronchodilators are the first-choice option for the treatment of stable COPD. Chest,2004,125 ( 1 ) :9-11.
  • 10Bamea PJ, Stochley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J,2005,25 ( 6 ) : 1084-1106.

二级参考文献15

  • 1Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci,1993,52:521-527.
  • 2Eglen RM,Reddy H,Watson N,et al. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol Sci,1994,15:114-119.
  • 3Hansel TT,Barnes PJ. Tiotropium bromide:a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc),2002,38:585-600.
  • 4Littner MR,Ilowite JS,Tashkin DP,et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2000,161(4 Pt 1):1136-1142.
  • 5Casaburi R,Briggs DD Jr,Donohue JF,et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD:a 13-week multicenter trial. The US Tiotropium Study Group. Chest,2000,118:1294-1302.
  • 6Casaburi R,Mahler DA,Jones PW,et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J,2002,19:217-224.
  • 7Calverley PM,Lee A,Towse L,et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax,2003,58:855-860.
  • 8Tashkin D,Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest,2003,123:1441-1449.
  • 9Donohue JF,van Noord JA,Bateman ED,et al. A 6-month,placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest,2002,122:47-55.
  • 10Donohue JF,Menjoge S,Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med,2003,97:1014-1020.

共引文献5137

同被引文献8

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部